Human and Mouse <i>VEGFA</i> -Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment

Abstract

Using a mouse model of inflammation-driven cancer, we identified a subclass of HCC carrying VEGFA amplification, which is particularly sensitive to VEGF-A inhibition. We found that a similar amplification in human HCC identifies patients who favorably responded to sorafenib-the first-line treatment of advanced HCC-which has an overall moderate therapeutic efficacy.